As with any medicine, the MHRA will keep the safety and effectiveness of vimseltinib (romvizma) under close review.
Want to keep yourself up to date with the latest news from Medicines and Healthcare products Regulatory Agency - Activity on GOV.UK?
Subscribe using the "Follow" button below and we provide you with customized updates, via topic or tag, that get delivered to your email address, your smartphone or on your dedicated news page on follow.it.
You can unsubscribe at any time painlessly.
Title of Medicines and Healthcare products Regulatory Agency - Activity on GOV.UK: "GOV.UK"